MDT-AP-1167
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 24
- os_event
- false
- age_years
- 9
- sex
- F
- new_clusters
- C2
- umap1_2d
- 2.836249502
- umap2_2d
- 1.369496141
- umap1_3d
- -0.322857034
- umap2_3d
- -2.962991291
- umap3_3d
- -1.525905588
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.390
- WNT_BETA_CATENIN_SIGNALING+0.340
- APICAL_SURFACE+0.290
- KRAS_SIGNALING_DN+0.290
- NOTCH_SIGNALING+0.270
- ESTROGEN_RESPONSE_EARLY+0.200
- APICAL_JUNCTION+0.130
- HYPOXIA+0.110
- MYC_TARGETS_V2+0.110
- BILE_ACID_METABOLISM+0.090
Top 10 suppressed
- E2F_TARGETS-0.580
- G2M_CHECKPOINT-0.540
- MYC_TARGETS_V1-0.400
- MITOTIC_SPINDLE-0.370
- PROTEIN_SECRETION-0.360
- DNA_REPAIR-0.310
- MTORC1_SIGNALING-0.310
- OXIDATIVE_PHOSPHORYLATION-0.300
- PI3K_AKT_MTOR_SIGNALING-0.290
- UNFOLDED_PROTEIN_RESPONSE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R76 | — | — | 0.843 |
| 2 | MDT-AP-1166 | Med | Medulloblastoma | 0.835 |
| 3 | MBCProject_0003_T2_RNA | — | A | 0.826 |
| 4 | TCGA-D8-A3Z5-01A-41R-A24H-07 | — | A | 0.825 |
| 5 | AUR-AER6-TTM10-A-1-1-R-A742-41 | — | C | 0.815 |
| 6 | SRR1313105 | — | A | 0.812 |
| 7 | MDT-AP-1121 | Med | Medulloblastoma | 0.808 |
| 8 | MBCProject_3672_T1_RNA | — | B | 0.805 |
| 9 | d406bb03-1a9a-4aa3-a1a8-4de5478b4701 | — | — | 0.803 |
| 10 | 12305e97-f72f-4de7-9735-4cdbecb60296 | — | — | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.340 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.010 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |